drugset
drugset / Trial / NCT05247489

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo

NCT05247489 ↗

Phase 2 Completed 55 enrolled Incyte Corporation
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of Ruxolitinib cream with or without phototherapy in adolescent and adult participants with non-segmental vitiligo for whom vitiligo area (facial and nonfacial) does not exceed 10% body surface area (BSA).

Timeline

Start
2022-05-05
Primary completion
2023-12-19
Completion
2023-12-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Ruxolitinib Small molecule 1.5 % —

Indications

vitiligo